aTyr Pharma financials
$0.3077+3.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $190.0K | $235.0K |
| Gross profit | $190.0K | $235.0K |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$77.6M | -$67.9M |
| Net income | -$74.1M | -$64.0M |
| Net margin | −39009.5% | −27243.8% |
| Diluted EPS | $-0.80 | $-0.86 |
| EBITDA | -$77.0M | -$67.2M |
| Operating cash flow | -$62.0M | -$69.1M |
| Free cash flow | -$62.1M | -$69.2M |
| Diluted shares | 93.0M | 74.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $10.7M | $11.1M |
| Short-term investments | $67.9M | $61.1M |
| Total debt | $889.0K | $1.4M |
| Total assets | $93.0M | $96.8M |
| Total liabilities | $25.7M | $27.0M |
| Shareholders' equity | $67.3M | $69.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology